Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. announced the completion of its previously announced merger with Galera Therapeutics, Inc. Concurrently, Obsidian completed an oversubscribed $350 million private placement financing. The combined company will operate as Obsidian Therapeutics, focusing on advancing its engineered TIL cell therapies for solid tumors. The financing is expected to provide a cash runway into the second half of 2028, supporting key clinical milestones for its lead product candidate, OBX-115.